E.E. Geduld’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

E.E. Geduld’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-10,000	Closed	-$110K	–	282
2015 Q2	$110K	Hold	10,000	–	–	0.07%	209
2015 Q1	$140K	Hold	10,000	–	–	0.09%	177
2014 Q4	$169K	Hold	10,000	–	–	0.09%	147
2014 Q3	$134K	Hold	10,000	–	–	0.09%	164
2014 Q2	$127K	Buy	+10,000	New	+$104K	0.08%	217

Other funds holding INFI

ACM

Americafirst Capital Management Roseville, California $74M AUM 30.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

E.E. Geduld's INFI Position: Q3 2015 in Review

E.E. Geduld sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2015, closing a stake of 10,000 shares — an estimated $110K sold.

E.E. Geduld first reported a position in INFI in Q2 2014 and held it in 5 quarters. The position peaked at $169K in Q4 2014. 129 funds tracked by Wall St. Rank hold INFI as of Q3 2015.

E.E. Geduld reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
E.E. Geduld sold 10,000 Infinity Pharmaceuticals, Inc. shares in Q3 2015, an estimated $110K.
E.E. Geduld first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2014 and held it in 5 quarters.
E.E. Geduld's Infinity Pharmaceuticals, Inc. position peaked at $169K in Q4 2014.
129 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2015.

Based on E.E. Geduld's 13F filing for Q3 2015, filed 6 Nov 2015.